to patients with dry eye and chronic problems of the surface of the eye, will offer PROSE treatment to patients with conditions including Stevens Johnson Syndrome, Keratoconus, Sjögren's syndrome and chronic ocular graft-versus-host disease (GVHD).Since 2006, the FDA has required McNeil to
Read more ...
No comments:
Post a Comment